Can Fite Biofarma Shares Up 6.7% After Co. Gave Update On Phase II Trial Of Namodenoson For Advanced Liver Cancer; Co. Said Accumulated Safety Data Indicates 'Favorable' Drug Safety Profile
Benzinga Newsdesk